Results
eNauka >
Results >
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
| Title: | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study | Authors  : | Cho, Byoung Chul; ...; Secen, Nevena M; ...; (broj, koautora 19) | Issue Date: | 2022 | Publication: | LANCET ONCOLOGY | ISSN: | 1470-2045 Lancet Oncology Search Idenfier |
Type: | Article | Collation: | vol. 23 br. 6 str. 781-792 | DOI: | 10.1016/S1470-2045(22)00226-1 | WoS-ID: | 000831830800023 | Scopus-ID: | 2-s2.0-85130688627 | URI: | https://enauka.gov.rs/handle/123456789/802568 | Project: | Genentech F Hoffmann-La Roche |
Metadata source: | (Preuzeto iz Nasi u WoS) | M-category: | 21a+M21a+ |
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.